Key statistics
On Tuesday, ATAI Life Sciences NV (9VC:FRA) closed at 2.25, -9.31% below its 52-week high of 2.48, set on Feb 06, 2025.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 1.82 |
---|---|
High | 2.44 |
Low | 1.82 |
Bid | 2.19 |
Offer | 2.41 |
Previous close | 1.88 |
Average volume | 18.95k |
---|---|
Shares outstanding | 200.75m |
Free float | 151.04m |
P/E (TTM) | -- |
Market cap | 439.65m USD |
EPS (TTM) | -0.9129 USD |
Data delayed at least 15 minutes, as of Jul 01 2025 17:48 BST.
More ▼
- atai Life Sciences Announces $50 Million Private Placement Financing
- atai Life Sciences and Beckley Psytech Announce Positive Topline Results from the Phase 2b Study of BPL-003 in Patients with Treatment-Resistant Depression
- atai Life Sciences and Beckley Psytech to Combine Creating a Global Leader in Psychedelic Mental Health Therapies
- atai Life Sciences to Participate in Upcoming Investor Conferences
- atai Life Sciences Announces Positive Topline Data from Part 2 of Beckley Psytech’s Phase 2a Study of BPL-003 in Combination with SSRIs for Treatment-Resistant Depression
- atai Life Sciences Reports First Quarter 2025 Financial Results and Recent Corporate Updates
- atai Life Sciences Announces First Patient Dosed in Phase 2 Study of EMP-01 for the Treatment of Social Anxiety Disorder
- atai Life Sciences Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights
- atai Life Sciences Announces First Patient Dosed in Elumina, the Phase 2 Clinical Trial of VLS-01 for Treatment-Resistant Depression
- atai Life Sciences Announces Completion of Enrollment in Phase 2b Clinical Trial Evaluating BPL-003 for Treatment-Resistant Depression
More ▼